Drug Safety
The US Preventive Services Task Force (USPSTF) has updated its recommendations regarding the efficacy of supplements or multivitamins for reducing the risk of cardiovascular disease, cancer, and mortality in the general adult population.

Dr. John Cush RheumNow
3 years 3 months ago
Of the Top 20 most expensive drugs in USA in 2022, only two are for rheumatic reasons. Unfortunately both are for ACTH preparations, once cheap, now devastatingly expensive: #11 Acthar Gel ($41,459/month) & #19 Cortrophin Gel ($30,083) https://t.co/avUZNVnHRp https://t.co/mXLhD8vJ6A

Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female patients is unexplained.

Dr. John Cush RheumNow
3 years 3 months ago
It's time to exonerate methotrexate in causing or exacerbating fibrotic interstitial lung disease in #RA patients https://t.co/AuEIWn8Pc4 https://t.co/razVTF6fFX


Dr. John Cush RheumNow
3 years 3 months ago
Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/pCxDqzXGHQ https://t.co/ExZkXSliFo

A pooled analyses of data from eight, phase 2 and 3 randomized clinical trials shows bimekizumab, a dual IL-17A/F inhibitor, to be effective in plaque psoriasis and was well tolerated aside from an increased incidence of mild to moderate oral candidiasis.
Aside from cost, there are significant concerns regarding efficacy and safety outcomes and recovery time. These issues are compounded with the need for bilateral TKR, wherein the patient and surgeon need to decide whether to have both TKRs done simultaneously or staged (single TKR one after another with a recovery period in between).

Dr. John Cush RheumNow
3 years 3 months ago
Jakne (acne) with upadacitinib: review of 857 Psoriasis pts on UPA by wk 16 9.8-15.2% c/o mild/moderate acne; only 2 D/C for acne. Higher rates seen among younger, female, non-White patients. (This rare in RA!) https://t.co/cN6NU7e5sb https://t.co/JAMYS8EIwN


Dr. John Cush RheumNow
3 years 3 months ago
Long term risk of Herpes zoster in 1157 pts on tofacitinib for ulcerative colitis was Tofa 3.62 vs PBO 1.98/100PY during induction; during maintenace was Tofa 5mg 2.05 vs 10 mg 6.64 vs PBO 0.97/100PY. Higher risk w/ age, low wt, prior TNFi, N.American https://t.co/E3PGvejAUF https://t.co/k8PIT2o5KI


Dr. John Cush RheumNow
3 years 3 months ago
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.
https://t.co/PoIheshd2n https://t.co/gjTN2Uz4IP https://t.co/OAfLRvSFBs


Dr. John Cush RheumNow
3 years 3 months ago
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj


Dr. John Cush RheumNow
3 years 3 months ago
Flares Not Increased Following RZV Injections
Insurance claims analysis has shown that the use of the RZV for prevention of HZ was highly used in patients with IMIDs and was safe, as higher rates of arthritis flares were not evident.
https://t.co/E27oIBlEDb https://t.co/VbtDnmRYzO
